Cat Allergen Immunotherapy for Allergy

(LYNX Trial)

This trial explores the effects of cat allergen immunotherapy on individuals allergic to cats. It examines whether exposure to cat allergens alters the types of immune cells in participants' bodies by comparing those already receiving treatment to those who are not. The study includes two groups: one group has undergone subcutaneous immunotherapy (shots under the skin) for at least a year, while the other group has never received such treatment. Ideal participants have moderate to severe cat allergies that disrupt daily life or sleep but do not suffer from severe asthma or frequent sinus infections. As an Early Phase 1 trial, this research aims to understand how the treatment works in people, offering participants a chance to contribute to groundbreaking allergy research.

The trial does not specify if you need to stop taking your current medications. However, if you are in the No immunotherapy cohort, you cannot be on any form of allergen immunotherapy. Also, certain medications like systemic corticosteroids and immunosuppressants should not have been used recently before screening.

Research has shown that cat allergen immunotherapy, specifically subcutaneous immunotherapy (SCIT), is generally safe. Most side effects are mild and occur at the injection site, such as redness or swelling. For example, one study found that using a modified cat allergen in SCIT mainly caused mild, delayed reactions at the injection site. Another study highlighted that a product called Dpg-pol-cat used in SCIT had an excellent safety record, making it a good option for treating cat allergies.

Unlike the standard treatments for cat allergies, which typically involve antihistamines or corticosteroids to manage symptoms, Cat Allergen Immunotherapy aims to address the root cause of the allergy by gradually desensitizing the immune system to cat allergens. Researchers are excited about this approach because it has the potential to provide long-term relief, reducing the need for ongoing medication. This therapy uses precise allergen exposure to train the immune system, which is different from traditional methods that primarily focus on symptom control.

Research has shown that subcutaneous immunotherapy (SCIT) for cat allergies can effectively reduce symptoms. One study demonstrated that SCIT greatly improved quality of life and decreased the need for medication in people with moderate to severe cat allergies. Another study found that after 12 months of treatment, patients were very satisfied and experienced fewer allergic reactions. In this trial, participants in the SCIT cohort will have been on maintenance dosing for at least one year. SCIT works by gradually helping the body get used to cat allergens, which trigger allergies. The treatment is generally safe, with most side effects being mild, such as swelling at the injection site.¹²³⁶⁷